Published in Mol Ther Oncolytics on December 10, 2014
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Innate immune recognition. Annu Rev Immunol (2001) 26.65
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Cancer immunotherapy comes of age. Nature (2011) 12.35
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2006) 10.73
Dendritic cells: specialized and regulated antigen processing machines. Cell (2001) 10.44
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8.63
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol (2005) 5.97
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med (2000) 5.74
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J (2010) 3.99
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol (2005) 2.64
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol (2011) 2.05
Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
Molecular characteristics of immunogenic cancer cell death. Cell Death Differ (2007) 1.92
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol (2002) 1.90
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res (2007) 1.77
Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med (1967) 1.75
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 1.75
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res (2011) 1.63
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer (2008) 1.62
OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg (2009) 1.40
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother (2010) 1.37
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36
Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology (2013) 1.35
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol (2014) 1.29
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 1.29
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med (2012) 1.29
Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res (2012) 1.28
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res (2012) 1.28
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005) 1.24
Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets (2007) 1.22
Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest (2009) 1.22
Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol (2012) 1.18
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother (2011) 1.18
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol (2009) 1.17
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther (2011) 1.16
Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res (2005) 1.15
Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther (2010) 1.15
OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther (2002) 1.13
Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol (2011) 1.13
CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol (2003) 1.12
Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol (2002) 1.11
Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast (2008) 1.06
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. Front Immunol (2014) 1.03
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine (2006) 1.02
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res (2004) 1.01
Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther (2008) 0.99
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother (1992) 0.98
Antitumor activity mediated by CpG: the route of administration is critical. J Immunother (2011) 0.96
Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine (2010) 0.95